Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SG 2000

Drug Profile

SG 2000

Alternative Names: BN-2629; NCI 694501; NSC 694501; Project P011; SJG-136; SP 2001; UP-2001

Latest Information Update: 03 Dec 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Spirogen
  • Developer National Cancer Institute (USA); Spirogen
  • Class Benzodiazepines; Cytostatic antibiotics; Pyrroles
  • Mechanism of Action DNA cross linking agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Acute myeloid leukaemia; Chronic lymphocytic leukaemia
  • Discontinued Fallopian tube cancer; Ovarian cancer; Peritoneal cancer

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 03 Dec 2015 Spirogen terminates a phase I/II trial for Chronic lymphocytic leukaemia and Acute myeloid leukaemia (Second-line therapy or greater, Late stage disease) in USA (NCT02034227)
  • 15 Oct 2013 Spirogen has been acquired by MedImmune
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top